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BRIEF REPORT: CLINICAL SCIENCE
Relationship Among Viral Load Outcomes in HIV
Treatment Interruption Trials
Graham C. Treasure,*† Evgenia Aga, MSc,‡ Ronald J. Bosch, PhD,‡ John W. Mellors, MD,§
Daniel R. Kuritzkes, MD,*Michael Para, MD,k Rajesh T. Gandhi, MD,¶ and Jonathan Z. Li, MD, MMSc*
Abstract: Viral load (VL) rebound timing and set point were
analyzed in 235 participants undergoing analytic treatment interrup-
tion (ATI) in 6 AIDS Clinical Trials Group studies. There was no
signiﬁcant association between rebound timing and ATI VL set point
for those who rebounded #12 weeks. VL set points were lower in
participants with rebound .12 weeks (P , 0.001) and participants
treated during early infection (P , 0.001). Pre-antiretroviral therapy
VL correlated with set point, though 68% of participants had a set
point lower than pre-antiretroviral therapy VL. These results
illustrate complex relationships between post-ATI virologic out-
comes and the potential presence of biological factors mediating
rebound timing and set point.
Key Words: HIV, treatment interruption, set point, viral rebound,
outcome
(J Acquir Immune Deﬁc Syndr 2016;72:310–313)
INTRODUCTION
Antiretroviral therapy (ART) is effective at controlling
HIV, and can suppress the plasma viral load (VL) below
levels of detection. However, when treatment is stopped, the
virus will almost inevitably rebound. The search continues for
an HIV “functional cure,” an intervention that allows for
sustained, ART-free virologic remission. Clinical efﬁcacy of
such interventions will need to be tested in analytic treatment
interruption (ATI) trials. However, the interpretation of ATI
studies has been complicated by the use of varying virologic
outcome measures, making comparisons and relative evalua-
tions between ATI trials difﬁcult.
VL set point has historically been the most commonly
used virologic endpoint in ATI trials,1–3 but recent studies
have also begun evaluating the timing of viral rebound in
a study design that has been termed an intensely monitored
antiretroviral pause.4–7 However, little is known about the
relationship between these 2 virologic outcomes. In addition,
it has been postulated that pre-ART VL and ATI VL set point
are nearly identical1 and the difference between pre-ART VL
and ATI VL set point has been used as a marker of
therapeutic efﬁcacy in previous studies.1,3,8–10 Using a pooled
dataset of 6 AIDS Clinical Trials Group (ACTG) ATI
studies, we performed an in-depth characterization of ATI
VL endpoints.
METHODS
Study Population
Participants in 6 ACTG ATI studies (ACTG 371,11
A5024,12 A5068,13 A5170,14 A5187,15 and A51972) were
included if they were on suppressive ART, received no recent
immunologic interventions (eg, therapeutic vaccination), and
had HIV-1 RNA ,50 copies per milliliter at the time of ATI.
Protocols ACTG 37111 and A518715 enrolled participants
treated within 6 months of infection. Participants in ACTG
371 were treated for 52 weeks before the ATI; those in A5187
had to be on a stable ART with HIV-1 RNA ,50 copies per
milliliter for at least 6 months before enrollment.
Statistical Analysis
The time to viral rebound was deﬁned as the week at
which there was a conﬁrmed HIV RNA $200 copies per
milliliter. VL set point was deﬁned as the mean viral load
between weeks 12 and 16. Associations between set point and
timing of viral rebound were analyzed using Spearman
correlation, Kruskal–Wallis, Mann–Whitney, and x2 tests.
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The correlation of pre-ART VL vs. ATI set points was
analyzed by Spearman correlation and Wilcoxon signed-rank
test. We also performed a sensitivity analysis of all partic-
ipants who underwent ATI in which those who discontinued
the ATI before week 12 were assigned a set point viral load
equal to their last known viral load.
RESULTS
Participants
Of the 235 participants, 91% were male, 71% were
white, 14% Hispanic, 13% black, and 3% others. Participants
in this study had a median age of 41 years. Sixty-six percent
were treated during chronic infection and 34% during early
infection. The median CD4+ cell count at the start of ATI was
827 cells per millimeter cube. Participants treated during
chronic infection had a median (Q1, Q3) of 5.1 (3.2, 6.5)
years on ART.
HIV Rebound Timing and Set Point
For participants who had HIV rebound at or before
week 12, there was no signiﬁcant association between
timing of viral rebound and the VL set point (Figs. 1A, B).
However, participants who rebounded after week 12 also
showed much lower set points [rebound #12 (N = 180)
vs. .12 weeks (N = 14): median 4.1 vs. 1.9 log10 HIV RNA
copies per milliliter, P , 0.001]. Lower ATI set points were
more frequent among those with delayed viral rebound.
Speciﬁcally, 10 of 154 (6.5%) participants who rebounded
within the ﬁrst 4 weeks had VL set points ,1000 RNA
copies per milliliter, as compared with 7 of 57 (12.3%) who
rebounded in weeks 5–8, 1 of 10 (10%) who rebounded in
weeks 9–12, and 11 of 14 (79%) who rebounded after week
12 (x2, P , 0.001; Figure S1A, Supplemental Digital
Content, http://links.lww.com/QAI/A796). We also per-
formed a sensitivity analysis in which the last available
VL measurement was used for 41 participants who did not
reach week 12 of the ATI. The results were largely
unchanged, reafﬁrming the original ﬁndings.
Participants treated during early infection were found to
have a lower VL set point (early vs. chronic: median 3.5 vs.
4.2 log10 HIV RNA copies per milliliter, P, 0.001, Fig. 1C).
No signiﬁcant difference was observed in VL set point
between those on nonnucleoside reverse transcriptase inhib-
itor or protease inhibitor-based ART regimens.
Association Between Pre-ART VL and ATI
VL Endpoints
In the 96 chronically treated participants who had both
pre-ART VL and ATI set point data, there was a signiﬁcant
correlation between these 2 measures (Spearman r = 0.39,
P , 0.001, Fig. 2A). The VL set point tended to be lower
than the pre-ART VL with a median 2-fold decrease by
patient (Q1, Q3: 5-fold decrease, 1.8-fold increase, Fig. 2B).
Furthermore, 68% of participants had VL set points lower
than pre-ART levels. The results were largely unchanged in
FIGURE 1. Analysis of post-ATI VL endpoints. A, VL set points
and median by rebound category. B, Median VLs categorized
by viral rebound week using a 2-week window for each time
point with the number of observations per category per time
point listed below. C, VLs for all patients shown, with median
VLs of chronic and acutely treated participants in solid and
dashed lines, respectively.
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the sensitivity analysis using the last available VL for
participants who did not reach ATI week 12 (pre-ART VL
vs. ATI VL set point Spearman r = 0.40, P, 0.001; median 2
fold decrease; and 68% of participants with lower VL set
point vs. pre-ART VL). No signiﬁcant association was found
between pre-ART VL and time to viral rebound, although
there were relatively few participants in the viral rebound
.12 week group with available pre-ART VL data.
DISCUSSION
HIV treatment interruption trials are expected to play
a key role in evaluating the efﬁcacy of interventions aimed at
achieving sustained HIV remission. The comparison of
interventions between ATI studies has been hindered by the
heterogeneity in virologic outcomes and uncertainty in how to
interpret trials without a placebo control arm. In this study, we
found that the timing of viral rebound and ATI VL set point
were largely independent when viral rebound occurred at or
before ATI week 12. However, those who rebounded after
week 12 were found to have signiﬁcantly lower ATI VL set
point. In addition, participants treated during early HIV
infection were found to have lower ATI VL set point,
a ﬁnding that is consistent with other studies that show
favorable rebound kinetics for those treated during early
stages of infection.16,17Although we observed a correlation
between pre-ART VL and ATI VL set points, the VL set
point was frequently lower than the pre-ART VL with a wide
range in possible outcomes.
Traditionally, ATI studies have used VL set point as
a common endpoint for therapeutic efﬁcacy. However, given
the concern for prolonged participant exposure to rebound
viremia, an alternative treatment interruption study design
termed the intensively monitored antiretroviral pause has
gained in popularity.4 This approach uses the time to viral
rebound as the primary endpoint, which may entail less risk to
the participants and act as a more clinically relevant outcome.
However, little is known about the relationship between these
2 primary study endpoints. The results of this study show that
for individuals who rebound at or before ATI week 12, there
is no signiﬁcant correlation between the timing of viral
rebound and the VL set point. Thus, interventions that confer
a modest delay in viral rebound timing may not necessarily
have a signiﬁcant effect on VL set point. Interestingly, we
found that those who rebounded after week 12 had signiﬁ-
cantly lower VL set points, suggesting the potential presence
of immunologic and/or virologic factors in this subset of
participants that can both delay viral rebound and suppress
the VL set point. It is important to note that even drastically
delayed viral rebounds are not always associated with lower
set points, especially in those whose immune system are
relatively naive to HIV. This was seen in the 2 Boston
patients who underwent allogeneic stem cell transplantation
with both delayed viral rebound timing and high levels of VL
after ATI.6
A previous study observed that the pre-ART viral load
appeared to be “virtually identical” to the ATI VL set point.1
This observation would suggest that a change in VL between
the ATI set point and pre-ART VL could be used as a study
endpoint and may especially be useful in those studies
without a control arm. In fact, lower ATI set point compared
with pre-ART VL has been presented as evidence of
therapeutic efﬁcacy in several ATI studies.8–10 However,
our results show that in more than two-thirds of participants,
the ATI VL set point was lower than the pre-ART VL. The
median value was a 2-fold lower VL set point with the 25th
and ﬁfth percentiles encompassing a 5-fold and 50-fold lower
VL set points compared with pre-ART VL, respectively.
There are a number of possible causes for this tendency for
VL set point to be lower. These include a smaller HIV
reservoir after sustained ART,18,19 immune reconstitution
after ART,20 or that 16 weeks of ATI is insufﬁcient time to
allow the VL to return to pre-ART levels.21 The overall lower
ATI VL set point and wide range of possible outcomes
suggest that the comparison with pre-ART VL should be
interpreted cautiously and may be a less accurate reﬂection of
therapeutic efﬁcacy than previously thought.
One notable limitation of this analysis is that a subset of
individuals who initiated ATI stopped the treatment interrup-
tion phase of the studies before ATI week 12. These
individuals could have potentially reached alternate criteria
for ART reinitiation, including rapid viral rebound, biasing
the analysis to those with lower VL set points. Therefore, we
performed sensitivity analysis with a carry forward of the last
recorded VLs as the VL set point for participants who did not
reach ATI week 12. The results were comparable to the
primary analysis, reafﬁrming the original conclusions.
Another limitation of the analysis is that only a subset of
chronically infected participants (N = 96) have available pre-
ART VL. However, the numbers were sufﬁciently substantial
to demonstrate the wide variance of VL set point in relation to
pre-ART VL and the risks associated with the use of the
comparison as an indicator of therapeutic efﬁcacy.
HIV ATI trials represent the most conclusive strategy
for evaluating the efﬁcacy of HIV curative therapies. A
detailed understanding of ATI VL endpoints is needed for the
optimal design and interpretation of these trials. Our results
FIGURE 2. Relationship of pre-ART viral load and post-ATI set
point. A, Plot of pre-ART VL vs. set point for 95 chronically
infected patients for whom data were available. B, Percentile
data for fold change of ATI VL set point to pre-ART VL (non
log10 transformed). Fold change represents post-ATI set point
divided by pre-ART viral load.
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revealed the complex relationship between several key
virologic factors, including pre-ART VL, viral rebound
timing, and VL set point. The results underscore the
difﬁculties in interpreting uncontrolled ATI studies. In
addition, the association of delayed viral rebound with
suppressed VL set point suggests the presence of key
immunologic and/or viral factors mediating both of these
outcomes and this observation deserves further study.
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